Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on MASI: Masimo CorpShs NewsMORE ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Masimo originally requested $1.85 billion in damages, along with reasonable royalties, lost profits, and a penalty for willful trade secret appropriation. With the bench trial, Masimo is no longer ...

The jury voted 6 to 1 in favor of Apple on these claims. Furthermore, the judge ruled against Masimo's claims regarding Apple's hiring practices, noting that employees can move between companies.

Full-Year 2024 Non-GAAP EPS Guidance: $3.95 to $4.10. Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for ...

Return on Equity (ROE): Masimo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.17%, the company may face hurdles in generating ...

However, Masimo's fourth-quarter revenue guidance of $581-611 million fell below the $607.5 million analyst consensus at the midpoint. The company expects fourth-quarter EPS between $1.35 and $1. ...